Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from University of Toronto, Department of Medical Biophysics describe findings in cancer gene therapy
April 28th, 2009
Current study results from the report, 'Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells,' have been published. "Adoptively transferred T cells possess anticancer activities partially mediated by T-cell FasL engagement of Fas tumor targets. However, antigen-induced T-cell activation and clonal expansion, which stimulates FasL activity, is often inefficient in tumors," scientists writing in the journal Cancer Gene Therapy report. "As a gene therapy approach to overcome this obstacle, we have created oncoretroviral vectors to overexpress FasL or non-cleavable FasL (ncFasL) on murine T cells of a diverse...
Source: Cancer Weekly (2009-04-28)
|
